Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
RNA molecule and robotic arm illustration

May 19, 2026

Sen. David McCormick Tours AI-Powered Biotech Labs at UPenn

Senator Dave McCormick recently toured the University of Pennsylvania's AIRFoundry, an innovative AI-focused lab dedicated to transforming biotech research and drug development.This facility, supported by the National Science Foundation, integrates artificial intelligence, robotics, and automation to expedite the creation of RNA-based therapies and other biotechnological advancements. The application of these technologies has the potential to compress lengthy drug development processes into mere
A minimalist illustration of a pill and a molecule in a dark palette.

May 19, 2026

Cohere buys Montreal’s Reliant AI in pharma market push

Cohere has made a strategic acquisition by purchasing Reliant AI, a Montreal-based company focused on developing AI technology for the pharmaceutical sector, as part of its initiative to penetrate specialized markets.This acquisition grants Cohere access to a range of global biotech clients and a skilled research team based in Canada and Germany. Reliant AI has created tools designed to streamline literature reviews and enhance the drug discovery process, utilizing advanced techniques like reinf
A DNA strand on a lab bench in a dimly lit laboratory

May 19, 2026

Twist Bioscience Corp stock (US90130A1016): biotech shares under pressure despite fresh AI drug disc

Twist Bioscience Corp's stock has recently experienced a downturn despite announcing a promising AI-driven drug discovery partnership with LenioBio, raising questions about the volatility of this biotech player.On May 18, 2026, Twist Bioscience Corp's shares fell approximately 7% to close at $49.17, following a period of strong price increases. This decline occurred shortly after the company revealed its collaboration with LenioBio, aimed at integrating automated DNA manufacturing with AI-led dr
Minimalist illustration of a DNA strand and oligonucleotide in dark colors with lime accents.

May 17, 2026

InSilico Ribo Oligonucleotide Alliance Tests AI Drug Discovery Model

InSilico Medicine has partnered with Suzhou Ribo Life Science to enhance AI-driven oligonucleotide drug development.This collaboration merges InSilico's advanced automation and AI capabilities with Ribo's specialized knowledge in oligonucleotide therapies, targeting various stages of the drug discovery process, including target identification and molecule design. This strategic alliance is noteworthy as oligonucleotide therapies are gaining traction in the pharmaceutical landscape, representing
A petri dish and pipette on a lab bench

May 17, 2026

OpenAI GPT-Rosalind: Inside the 0.751 BixBench Score and $2.6B Pharma Bet [2026]

OpenAI has launched GPT-Rosalind, a specialized AI model aimed at revolutionizing the pharmaceutical research sector, which is grappling with declining productivity and soaring drug development costs. This model, named after the renowned chemist Rosalind Franklin, is designed to enhance processes such as drug discovery, genomics analysis, and translational medicine.Released on April 16, 2026, GPT-Rosalind is part of a broader initiative by OpenAI to develop life sciences models. It has achieved
A flat illustration of a molecule structure on a solid background.

May 16, 2026

Schrodinger stock (US80655G1067): AI-powered drug discovery story after latest earnings

Schrodinger's recent quarterly report highlights its dual focus on AI-driven drug discovery and software revenue, drawing significant investor interest.Schrodinger has recently updated investors with its latest earnings, showcasing its AI-powered drug discovery platform alongside a breakdown of its software and drug discovery revenues. The company operates at the intersection of computational chemistry and biotechnology, providing tools that enable pharmaceutical and materials science firms to d
A test tube with a colorful drug compound on a lab bench

May 16, 2026

AI: Revolutionising Pharma R&D

AI is significantly transforming pharmaceutical research and development, moving from a traditional one-size-fits-all model to a more personalized approach.The pharmaceutical industry is experiencing a shift towards precision medicine, largely driven by artificial intelligence (AI). This technology harnesses large datasets and predictive analytics to create tailored therapies that consider individual patient characteristics, including genetics and lifestyle. By analyzing clinical and real-world
Minimalist illustration of a protein structure in dark tones with lime accents.

May 15, 2026

Google Launches REPLIQA to Integrate Quantum AI and Life Sciences

Google has unveiled the REPLIQA initiative, a $10 million program aimed at merging quantum AI with life sciences research.The Research Program at the Intersection of Life Sciences & Quantum AI (REPLIQA) seeks to leverage quantum mechanics to tackle complex biological processes that traditional computing struggles to simulate. Funded institutions include Harvard, MIT, UC San Diego, UC Santa Barbara, and the University of Arizona. The initiative aims to explore molecular phenomena such as protein
A bubbling chemical reaction in a glass beaker on a lab bench, surrounded by shelves of glassware.

May 15, 2026

Google-backed Isomorphic Labs Raises $ 2.1 Bn to Enhance AI-based Drug Discovery Platform

Isomorphic Labs, an AI-driven drug discovery company, has successfully raised $2.1 billion in a Series B funding round, primarily led by Thrive Capital and supported by Alphabet and Google’s GV. This significant investment aims to enhance its AI platform and therapeutic pipeline, further advancing its drug discovery capabilities.Founded by Demis Hassabis of Google DeepMind in 2021, Isomorphic Labs is leveraging predictive and generative AI models to innovate drug discovery processes. Central to
A minimalist illustration of a pill symbolizing drug discovery.

May 15, 2026

Google-Backed Isomorphic Labs Secures $2.1 Billion to Push AI Drug Discovery Forward

Isomorphic Labs, a London-based biotech firm backed by Google, has secured $2.1 billion in Series B funding to enhance its AI-driven drug discovery capabilities. This significant investment underscores the growing confidence in AI's potential to revolutionize pharmaceutical development, promising faster and more cost-effective drug design compared to traditional methods.Founded in 2021 by Demis Hassabis from Google DeepMind, Isomorphic Labs aims to leverage advanced AI technologies to transform
A minimalist illustration of a pill and capsule on a solid background.

May 15, 2026

Big Pharma Teams Up With AI Titans as the Race for “AI Bio” Innovation Intensifies

Big pharmaceutical companies are increasingly forming alliances with AI technology leaders to enhance drug development and regain competitive advantages in the market.Recent collaborations highlight this trend, with Novo Nordisk partnering with OpenAI to integrate artificial intelligence into various aspects of drug discovery, production, and supply chain management. This partnership aims to streamline processes and improve the efficiency of bringing new medications to market, particularly for o
AAV capsid and cell membrane illustration

May 14, 2026

Cell and Gene Therapy Catapult invests in Lir Therapeutics to accelerate development of its AI-driven AAV design platform

The Cell and Gene Therapy Catapult (CGT Catapult) is investing in Lir Therapeutics to enhance its AI-driven AAV capsid design platform, nAAVigator. This funding aims to facilitate biological validation and generate necessary data to attract pharmaceutical and biotech partnerships.Lir Therapeutics has developed a unique AI-based system that creates and selects novel adeno-associated virus (AAV) capsids, which are crucial for delivering gene therapies. These capsids transport therapeutic materials